Oxford BioDynamics Plc announced that it has appointed Dr. Bartu Ahiska as Senior Vice President (Commercial), to spearhead the commercialisation of the Group's EpiSwitch™ technology platform. Bartu Ahiska is an experienced entrepreneur, IP strategist and technology driver with experience in several fields including medical engineering, biologics, computing and graphics. He joins OBD from the Knight Cancer Early Detection Advanced Research Centre (CEDAR) at Oregon Health & Science University (OHSU) in Portland, Oregon, where he has been Innovation, IP & Commercialisation manager since 2016. He was a co-founder and remains a Non-Executive Director of Trogenex Inc. in San Diego, CA, and was COO and CEO of cloud-computing company Approxy before its acquisition by Numecent. Bartu joins OBD's expanding commercial team and will work closely with both Glen Ferguson, who was appointed Senior Vice President (USA) in March 2019, and the rest of the Group's executive management team.